Information processing system, information processing method, and program

Abstract

An information processing system is provided with: a first terminal that outputs a first hash value on the basis of data including at least object content, and transmits first proof data including either the first hash value or information based on the first hash value; the management system records first certification data received from the first terminal to the block chain, the management system reads out the first certification data recorded in the block chain and sends the data to the second terminal, and the second terminal obtains a first hash value included in the first certification data received from the management system and sends the first hash value to the block chain; and obtaining object content, generating a second hash value according to the object content, and judging whether the first hash value is consistent with the second hash value or not.

Description

Technical Field

[0001] The present invention relates to an information processing system, an information processing method and a program. Background Art

[0002] In cancer treatment so far, treatment and drugs are selected according to the type of cancer, such as lung cancer, colorectal cancer, and breast cancer. However, in the 2000s, the analysis of the molecules (proteins) that are the causes of cancer and the gene mutations that are the basis for it has made progress, and it has gradually become possible to use "molecular targeted drugs" that act on such molecules, genes, etc. for treatment. Further development from molecular targeted drugs, treatment methods that target individual molecules and gene mutations of patients are also developing. Here, not only the type of cancer, but also the characteristics of cancer such as gene mutations, will be combined to provide treatment suitable for each different person, which is called "personalized treatment." In the past, "personalized treatment" based on genetic information of cancer was mainly based on "cancer gene testing" that investigates a few genes and "cancer gene panel testing" that investigates multiple genes at the same time.

[0003] In recent years, cancer immunotherapy (hereinafter referred to as cancer vaccine therapy) has been further developed, which is to "attack and eliminate cancer cells through the action of the human immune system". As one of the cancer vaccine therapies, "peptide vaccines" are known. Peptide vaccines contain antigens that are markers of cancer. If a peptide containing the antigen is directly injected into the body, the human immune function detects abnormalities and attacks the antigens that are markers of cancer as targets, thereby killing cancer cells.

[0004] In recent years, it has become an era to comprehensively and easily know the genetic mutations of each patient's cancer. In cancer immunotherapy, the importance of "peptides" newly produced due to their genetic mutations has received attention. This peptide is a variant peptide called a "neoantigen". It is known that if they appear on the surface of cancer cells with human leukocyte antigens (Human Leukocyte Antigen: HLA), since they are peptides that do not exist on the surface of normal cells, cytotoxic T cells (Cytotoxic Tlymphocyte: CTL) regard them as enemies and can kill cancer cells. Currently, clinical trials are being conducted in Europe and the United States to confirm whether personalized cancer vaccine therapy using "neoantigens" is effective as a method of treating cancer or preventing recurrence. In addition, Patent Document 1 discloses a method for identifying fragments of immunogenic polypeptides for specific human subjects and a method for preparing a personalized pharmaceutical composition containing the polypeptide fragments.

[0005] Prior art literature

[0006] Patent Literature

[0007] Patent Document 1: Japanese Patent Application No. 2020-510698 Summary of the invention

[0008] The types and quantities of variant peptides called "neoantigens" vary from patient to patient, so it is necessary to produce peptide vaccines for each patient based on the gene mutations of the patient's cancer tissue. Here, in the case of personalized medicine (such as personalized cancer vaccine therapy), there is a process in which a gene analysis agency (such as a sequence supplier) analyzes the gene sequence of a patient's sample, a process in which a formulation preparation agency prepares a formulation of a drug (such as a cancer vaccine) for the patient based on the gene analysis results, and a process in which a drug manufacturing agency (such as a pharmaceutical company) manufactures a drug (such as a cancer vaccine) based on the formulation.

[0009] In the distribution process of producing such personalized medicines (eg, cancer vaccines), the authenticity of the gene sequence data (also called genome information) of the patient's sample or the vaccine data is required.

[0010] In addition, authenticity is required for specifications of drugs (such as personalized vaccines) that are specific to target patients and contracts for drugs (such as personalized vaccines) that are specific to target patients.

[0011] In addition, a mechanism is needed to ensure the authenticity of the manufacturing report of the drug dedicated to the target patient (e.g., personalized vaccine), the product testing report of the drug dedicated to the target patient (e.g., personalized vaccine), the delivery certificate of the drug dedicated to the target patient (e.g., personalized vaccine), or the receipt of the drug dedicated to the target patient (e.g., personalized vaccine).

[0012] Thus, a mechanism is required to ensure the authenticity of the target content (e.g., genomic data, formulation data, etc.) in the distribution process of the preparation of the target patient-specific medicine (e.g., personalized vaccine). Here, the target content is the target patient's genomic data, the formulation data for the target patient-specific medicine (e.g., personalized vaccine), the specification of the target patient-specific medicine (e.g., personalized vaccine), the contract of the target patient-specific medicine (e.g., personalized vaccine), the manufacturing report of the target patient-specific medicine (e.g., personalized vaccine), the product test report of the target patient-specific medicine (e.g., personalized vaccine), the delivery document of the target patient-specific medicine (e.g., personalized vaccine), or the receipt of the target patient-specific medicine (e.g., personalized vaccine).

[0013] In addition, the same treatment possibilities exist not only for cancer vaccines, but also for autoimmune diseases, and the same problems exist in personalized medicines for autoimmune diseases.

[0014] The present embodiment has been proposed in view of the above-mentioned problems, and one object thereof is to provide an information processing system, an information processing method, and a program capable of ensuring the authenticity of target content in the distribution process of production of personalized medicines.

[0015] Means for solving problems

[0016] An information processing system of a first embodiment of the present invention comprises a first terminal, a second terminal and a management system, wherein the first terminal outputs a first hash value based on data at least including object content, and sends first proof data, wherein the first proof data includes the first hash value or information based on the first hash value, the management system records the first proof data received from the first terminal to a blockchain, the management system sends the first proof data recorded in the blockchain to the second terminal, the second terminal obtains the first hash value based on the first proof data received from the management system, obtains the object content and generates a second hash value based on the object content, and determines whether the first hash value is consistent with the second hash value.

[0017] The information processing system of the second mode of the present invention is based on the information processing system of the first mode, wherein the first terminal is used by a gene analysis agency that generates genome information of the target patient based on the sample of the target patient, and the second terminal is used by a formulation preparation agency that prepares a vaccine formulation, and the target content is the genome information of the target patient.

[0018] The information processing system according to a third aspect of the present invention is the information processing system according to the second aspect, wherein the genome information of the target patient includes gene data of cancer cells of the target patient and gene data of normal cells of the target patient.

[0019] The information processing system of the fourth mode of the present invention is based on the information processing system of the first mode, wherein the first terminal is used by a formulation preparation organization that prepares vaccine formulations, and the second terminal is used by a drug manufacturing organization that manufactures personalized drugs based on the vaccine formulations, and the object content is the vaccine formulation for the target patient.

[0020] The information processing system of the fifth mode of the present invention is based on the information processing system of any one of the first to fourth modes. The information based on the above-mentioned first hash value is the information obtained by encrypting the above-mentioned first hash value by the first private key. When the above-mentioned first terminal sends the above-mentioned first proof data, it sends the information obtained by encrypting the above-mentioned first hash value by the first private key. When the above-mentioned second terminal obtains the above-mentioned first hash value contained in the above-mentioned first proof data, it decrypts the first proof data by using the first public key corresponding to the above-mentioned first private key, thereby obtaining the first hash value.

[0021] The information processing system of the sixth mode of the present invention is based on the information processing system of any one of the first to fifth modes. The first proof data received from the above-mentioned first terminal recorded in the above-mentioned blockchain contains drug identification information that identifies the personalized drug for the target patient. The above-mentioned second terminal sends second proof data containing the drug identification information and the first hash value or the second hash value when the above-mentioned first hash value is consistent with the above-mentioned second hash value. The above-mentioned management system records the second proof data received from the above-mentioned second terminal to the blockchain.

[0022] The information processing system of the seventh mode of the present invention is based on the information processing system of the sixth mode. The above-mentioned information processing system also has an authentication system. The above-mentioned authentication system uses the drug identification information of the object as a keyword to retrieve the block of the blockchain. When the search result is that the hash values ​​contained in the two obtained blocks are consistent, it is determined that the handover of the object content has been carried out normally.

[0023] The information processing system of the eighth mode of the present invention is based on the information processing system of the second or third mode. The above-mentioned information processing system also has a third terminal, and the third terminal is used by a drug manufacturing organization that manufactures personalized drugs according to vaccine formulas. The above-mentioned second terminal outputs a hash value based on data of at least a formula of the drug for the target patient, and sends third proof data, wherein the third proof data includes either a hash value or information based on the hash value. The above-mentioned management system records the third proof data received from the above-mentioned second terminal to the blockchain, and the above-mentioned management system sends the third proof data recorded in the above-mentioned blockchain to the above-mentioned third terminal. The above-mentioned third terminal obtains the fourth hash value included in the third proof data received from the above-mentioned management system, obtains the above-mentioned formula and generates a fourth hash value based on the formula, and determines whether the third hash value is consistent with the fourth hash value.

[0024] The information processing system of the ninth mode of the present invention is based on the information processing system of the eighth mode. When sending the third proof data, the second terminal sends the information obtained by encrypting the third hash value with the second private key. When obtaining the third hash value included in the third proof data, the third terminal decrypts the third proof data with the second public key corresponding to the second private key, thereby obtaining the second hash value.

[0025] The information processing system of the tenth mode of the present invention is based on the information processing system of the eighth or ninth mode. The third proof data received from the above-mentioned second terminal and recorded in the above-mentioned blockchain contains drug identification information that identifies the personalized drug for the target patient. When the above-mentioned third hash value is consistent with the above-mentioned fourth hash value, the above-mentioned third terminal sends fourth proof data containing drug identification information and the third hash value or the fourth hash value. The above-mentioned management system records the fourth proof data received from the above-mentioned third terminal to the blockchain.

[0026] The information processing system of the eleventh embodiment of the present invention is based on the information processing system of any one of the first to tenth embodiments, and the above-mentioned information processing system has a fourth terminal used by a medical institution and a fifth device used by a logistics company, the above-mentioned fourth terminal sends fifth proof data for proving that the sample of the target patient has been delivered from the medical institution to the logistics company, and the above-mentioned management system records the fifth proof data received from the above-mentioned fourth terminal to the blockchain, and the above-mentioned fifth terminal sends sixth proof data for proving that the logistics company has received the sample of the target patient from the medical institution, and the above-mentioned management system records the sixth proof data received from the above-mentioned fifth terminal to the blockchain.

[0027] The information processing system of the twelfth mode of the present invention is based on the information processing system of the eleventh mode, wherein the fifth proof data includes information obtained by encrypting the hash value of the text data for personalized medicine using the third private key used by the medical institution, and the sixth proof data includes information obtained by encrypting the hash value of the text data for personalized medicine using the fourth private key used by the logistics company.

[0028] The thirteenth aspect of the information processing method of the present invention comprises: a step in which the first terminal outputs a first hash value based on data at least including object content and sends first proof data, wherein the first proof data includes the first hash value or any one of information based on the first hash value; a step in which the management system records the first proof data received from the above-mentioned first terminal to the blockchain; a step in which the above-mentioned management system sends the first proof data recorded in the above-mentioned blockchain to the above-mentioned second terminal; and a step in which the above-mentioned second terminal obtains the first hash value based on the first proof data received from the above-mentioned management system, obtains the above-mentioned object content and generates a second hash value based on the object content, and determines whether the first hash value is consistent with the second hash value.

[0029] The program of the fourteenth embodiment of the present invention is used to cause a computer to execute the following steps: a step of obtaining a first hash value from first proof data recorded in a blockchain, wherein the first proof data includes a first hash value generated based on data at least including object content or any one of information based on the first hash value; a step of generating a second hash value based on the object content; and a step of determining whether the first hash value is consistent with the second hash value.

[0030] Effects of the Invention

[0031] According to one embodiment of the present invention, if the first hash value recorded in the blockchain is consistent with the second hash value generated based on the object content, it is ensured that the two are the same object content, so the authenticity of the object content can be ensured. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 It is a diagram for explaining the configuration of the information processing system according to the present embodiment.

[0033] Figure 2 This is a schematic diagram of the terminal structure of this embodiment.

[0034] Figure 3 This is a schematic configuration diagram of the management system according to this embodiment.

[0035] Figure 4 This is a schematic structural diagram of an authentication system according to an embodiment.

[0036] Figure 5 This is a schematic diagram showing an example of the outline of the process of creating a personalized medicine.

[0037] Figure 6 This is a schematic diagram showing an example of the flow of transferring files of target contents. DETAILED DESCRIPTION

[0038] Below, while referring to the attached Figure 1 Each embodiment is described. However, sometimes more detailed descriptions than necessary are omitted. For example, sometimes detailed descriptions of well-known matters and repeated descriptions of substantially the same structures are omitted. This is to avoid the following description from becoming unnecessarily lengthy and to make it easy for those skilled in the art to understand.

[0039] In addition, in the distribution process of personalized medicine (e.g., cancer vaccine), for the gene sequence data (also called genome data) of the patient's sample, a mechanism is required to ensure that the gene analysis agency that generated the data is the production party. Similarly, in the distribution process of personalized medicine (e.g., cancer vaccine), for the vaccine formulation data, a mechanism is required to ensure that the formulation production agency that produced the vaccine formulation is the production party.

[0040] Similarly, for specifications of target patient-specific drugs (eg, personalized vaccines) and contracts for target patient-specific drugs (eg, personalized vaccines), a mechanism is required to ensure that the production organization that produced the drugs is the party responsible for production.

[0041] Similarly, with respect to manufacturing reports for drugs specifically for target patients (e.g., personalized vaccines), product testing reports for drugs specifically for target patients (e.g., personalized vaccines), delivery documents for drugs specifically for target patients (e.g., personalized vaccines), or receipts for drugs specifically for target patients (e.g., personalized vaccines), a mechanism is required to ensure that the manufacturing organization that produced the drugs is the party responsible for the production.

[0042] Thus, in addition to or instead of the above-mentioned problems, a mechanism for ensuring the authenticity of the production party who produced the target content is required in the distribution process of the production of personalized medicines.

[0043] Figure 1 The structure of the information processing system of this embodiment is described. Figure 1 As shown, the information processing system 10 includes a terminal 1 used by a gene analysis institution, a terminal 2 used by a formulation preparation institution, a terminal 3 used by a drug manufacturing institution, a terminal 4 used by a medical institution, and a terminal 5 used by a logistics company.

[0044] Here, the gene analysis agency generates genome information (also referred to as gene data) of the target patient based on the sample of the target patient. The sample of the target patient, for example, includes cancer tissue and normal tissue of the same target patient. In this case, the generated genome information of the target patient is the gene data (e.g., DNA data) of the cancer cells of the target patient and the gene data (e.g., DNA data) of the normal cells of the target patient. The formulation preparation agency prepares the vaccine formulation.

[0045] The information processing system 10 also includes a management system 6, an authentication system 7, a distributed network 8 for blockchain, and a storage device 9. The terminals 1 to 5, the authentication system 7, and the storage device 9 are respectively connected to the management system 6 via the communication network CN so as to be communicable. Here, the terminals 1 to 5 are computers such as smart phones, tablet terminals, laptop computers, or personal computers. The terminals 1 to 5 each have at least one processor and at least one memory, storing a unique private key. The authentication system 7 stores the public keys corresponding to the private keys held by each of the terminals 1 to 5. The data of the above-mentioned object content (for example, genetic data, vaccine formula data, etc.) is stored in the storage device 9.

[0046] In addition, the distributed network 8 has a plurality of computers (not shown), and these terminals are connected to each other in a P2P (Peer to Peer) manner as an example. Here, the P2P manner is a connection manner in which a plurality of equal computers directly communicate one to one. Blockchains 81 are stored in each of the plurality of computers in the distributed network 8. In the blockchain 81, information is stored by blockchain technology, for example, a historical record of handover in the circulation process of the production of personalized drugs is stored.

[0047] Since the terminals 1 to 5 have the same configuration, the configuration of the terminal 1 will be described below as a representative of the terminals 1 to 5 .

[0048] Figure 2 FIG. 1 is a schematic diagram of the terminal structure of the present embodiment. Figure 2 As shown, the terminal 1 has an input interface 11, a communication module 12, a storage device 13, a memory 14, an output interface 15, and a processor 16. In addition, as a mode, it is assumed that the terminal 1 has one processor 16 for explanation, but it can also be multiple, that is, it can have more than one processor. In addition, as a mode, it is assumed that the terminal 1 has one storage device 13 for explanation, but it can also be multiple, that is, it can have more than one storage device.

[0049] The input interface 11 receives input from, for example, a person in charge of a gene analysis organization, and outputs an input signal corresponding to the received input to the processor 16 .

[0050] The communication module 12 is connected to the communication network CN and communicates with the management system 6 and the storage device 9. The communication may be wired or wireless.

[0051] The storage device 13 is, for example, a storage device, and stores programs, inherent private keys, and various data for being read and executed by the processor 16. The memory 14 temporarily stores data and programs. The memory 14 is a volatile memory, for example, a RAM (Random Access Memory). The output interface 15 can be connected to an external device and can output a signal to the external device. The processor 16 loads a program from the storage device 13 to the memory 14, executes a series of commands included in the program, and thereby performs various processes.

[0052] Figure 3 This is a schematic diagram of the management system of this embodiment. Figure 3As shown, the management system 6 has an input interface 61, a communication module 62, a storage device 63, a memory 64, an output interface 65, and a processor 66. In addition, as a mode, the management system 6 is described as having one processor 66, but it can also be multiple, that is, it can have more than one processor. In addition, as a mode, the management system 6 is described as having one storage device 63, but it can also be multiple, that is, it can have more than one storage device.

[0053] The input interface 61 receives input from a manager of the management system 6 (for example, a staff member of the management group), and outputs an input signal corresponding to the received input to the processor 66 .

[0054] The communication module 62 is connected to the communication network CN, and communicates with each of the terminals 1 to 5, the authentication system 7, the blockchain 81, and the storage device 9. The communication may be wired or wireless.

[0055] The storage device 63 is, for example, a storage device, and stores programs and various data for being read and executed by the processor 66. The memory 64 temporarily holds data and programs. The memory 64 is a volatile memory, for example, a RAM (Random Access Memory). The output interface 65 can be connected to an external device and can output a signal to the external device. The processor 66 loads a program from the storage device 63 to the memory 64, and executes various processes by executing a series of commands included in the program.

[0056] Figure 4 FIG. 1 is a schematic diagram of the authentication system of this embodiment. Figure 4 As shown, the authentication system 7 has an input interface 71, a communication module 72, a storage device 73, a memory 74, an output interface 75, and a processor 76. In addition, as a mode, the authentication system 7 is described as having one processor 76, but it can also be multiple, that is, it can have more than one processor. In addition, as a mode, the authentication system 7 is described as having one storage device 73, but it can also be multiple, that is, it can have more than one storage device.

[0057] The input interface 71 receives input from an administrator of the authentication system 7 (eg, a staff member of an authentication organization), and outputs an input signal corresponding to the received input to the processor 76 .

[0058] The communication module 72 is connected to the communication network CN and communicates with the management system 6 and the blockchain 81. The communication can be wired or wireless.

[0059] The storage device 73 is, for example, a storage device that stores programs for being read out and executed by the processor 76, public keys corresponding to the private keys of the terminals 1 to 5 (i.e., 5 public keys), and various data. The memory 74 temporarily stores data and programs. The memory 74 is a volatile memory, for example, a RAM (Random Access Memory). The output interface 75 can be connected to an external device and can output a signal to the external device. The processor 76 loads the program from the storage device 73 to the memory 74, and executes various processes by executing a series of commands included in the program.

[0060] Figure 5 1 is a schematic diagram showing an example of the outline of the process of creating a personalized medicine. In one embodiment, first, in response to a request from a terminal 4 used by a medical institution, a dragID as an example of medicine identification information for identifying a personalized medicine is issued from the management system 6.

[0061] First, the dragID and the sample of the target patient (also referred to as a patient sample) are delivered from the medical institution to the logistics company. At this time, for example, the following processing is performed.

[0062] (Step S10 ) The terminal 4 transmits information on the sample of the target patient that has been handed over to the management system 6 .

[0063] (Step S11 ) The management system 6 records the information of the sample of the delivered patient received from the terminal 4 in the blockchain 81 .

[0064] (Step S12) The terminal 5 transmits information that the sample of the target patient has been collected to the management system 6.

[0065] (Step S13 ) The management system 6 records the information of the sample collected from the target patient received from the terminal 5 in the blockchain 81 .

[0066] Next, the dragID and the sample of the target patient are delivered from the logistics company to the gene analysis institution. At this time, for example, the following processing is performed.

[0067] (Step S20) The terminal 5 transmits information on the sample of the target patient that has been handed over to the management system 6.

[0068] (Step S21 ) The management system 6 records the information of the sample of the delivered patient received from the terminal 5 into the blockchain 81 .

[0069] (Step S22) The terminal 1 transmits information that the sample of the target patient has been collected to the management system 6.

[0070] (Step S23 ) The management system 6 records the information of the sample of the collected target patient received from the terminal 1 into the blockchain 81 .

[0071] Next, the gene analysis agency generates genome information of the target patient based on the sample of the genome target patient. In one embodiment, since the capacity of genome information is large, identification information of genome information is stored in blockchain 81, and genome information is stored in storage device 9. At this time, for example, the following processing is performed.

[0072] (Step S31) The management system 6 obtains the identification information of the genome information from the terminal 1, and records the identification information of the genome information to the blockchain 81. Here, the identification information of the genome information is, for example, Figure 6 The hash value of the genome information file encrypted by the terminal 1 using the private key of the terminal 1 (or the gene analysis agency) in step S160. In addition, the management system 6 can also generate identification information of the genome information. In the storage device 9, the genome information is stored by the terminal 1 or the management system 6, for example.

[0073] Next, a personalized medicine (e.g., a vaccine, specifically, a cancer vaccine) is formulated in a formulation making mechanism. In one embodiment, the personalized medicine formulation is formulated by referring to the genome information according to the identification information of the genome information. The personalized medicine formulation data is recorded in the storage device 9, and the identification information of the genome information is recorded in the blockchain 81. At this time, for example, the following processing is performed.

[0074] (Step S33) The management system 6 obtains the identification information of the genome information by referring to the blockchain 81 as an example. Here, the identification information of the genome information is, for example, Figure 6 The hash value of the genome information file encrypted by terminal 1 using the private key of terminal 1 (or gene analysis organization) in step S160.

[0075] (Step S34) Then, the management system 6 sends the identification information of the acquired genome information to the terminal 2. After that, the following steps are executed. Figure 6 Steps S210 to S260.

[0076] (Step S41) Next, the management system 6 obtains the formula identification information of the personalized medicine (e.g., vaccine, specifically, cancer vaccine) from the terminal 2, and records the formula identification information to the blockchain. Here, the formula identification information is, for example, Figure 6 The hash value of the recipe data file encrypted by the terminal 2 using the private key of the terminal 2 (or the recipe making organization) in step S160. In addition, the management system 6 may also generate the recipe identification information. The recipe data of the personalized medicine is recorded in the storage device 9 by the terminal 2 or the management system 6.

[0077] Next, in the drug manufacturing organization, personalized drugs (such as vaccines, specifically cancer vaccines) are manufactured. The drug manufacturing organization manufactures personalized drugs according to the formula identification information of the personalized drugs and the formula data of the personalized drugs. At this time, for example, the following processing is performed.

[0078] (Step S43) The management system 6 obtains the recipe identification information by referring to the blockchain 81 as an example. Here, the recipe identification information is, for example, Figure 6 The hash value of the recipe data file encrypted by terminal 2 using the private key of terminal 2 (or recipe preparation organization) in step S160.

[0079] (Step S44) Then, the management system 6 sends the obtained recipe identification information to the terminal 3. After that, the following steps are executed. Figure 6 The terminal 3 obtains the personalized medicine formula data from the storage device 9 according to the formula identification information and references the personalized medicine formula data. The medicine manufacturing organization manufactures the personalized medicine according to the personalized medicine formula data.

[0080] When the drug manufacturing organization has delivered the manufactured personalized medicine to the logistics company, for example, the following process is performed.

[0081] (Step S50) The terminal 3 transmits information on the delivered medicine to the management system 6.

[0082] (Step S51 ) The management system 6 records the information of the delivered medicine received from the terminal 3 into the blockchain 81 .

[0083] Next, when the logistics company has received the personalized medicine from the medicine manufacturing organization, for example, the following process is performed.

[0084] (Step S52) The terminal 5 transmits information on the received medicine to the management system 6.

[0085] (Step S53 ) The management system 6 records the information of the collected medicine received from the terminal 5 into the blockchain 81 .

[0086] Next, when the logistics company has delivered the personalized medicine to the medical institution, for example, the following processing is performed.

[0087] (Step S61) The terminal 5 transmits information on the delivered medicine to the management system 6.

[0088] (Step S62 ) The management system 6 records the information of the delivered medicine received from the terminal 5 into the blockchain 81 .

[0089] Next, when the medical institution has received the personalized medicine from the logistics company, for example, the following processing is performed.

[0090] (Step S63) The terminal 4 transmits information on the received medicine to the management system 6.

[0091] (Step S64 ) The management system 6 records the information of the collected medicine received from the terminal 4 into the blockchain 81 .

[0092] In this way, the information of the sample or personalized medicine of the delivered patient is gradually recorded in the blockchain 81, so that the delivered historical records will not be deleted or tampered with, so the correct historical records can be confirmed during or after the production process of personalized medicine.

[0093] In addition, the genome identification information or the formula identification information is recorded in the blockchain 81, so that the genome identification information or the formula identification information is recorded without being deleted or tampered with. Therefore, during or after the production process of the personalized medicine, the correct genome identification information or the formula identification information can be obtained, so that the correct genome information or formula data can be referenced and the correct genome information or formula data can be verified.

[0094] Figure 6 This is a schematic diagram of an example of the handover process of the file representing the object content. This process is performed in each step of handing over the above-mentioned object content. As an example, it is assumed that the object content is the genome information of the object patient, the sender is the terminal 1 used by the gene analysis agency, and the receiver is the terminal 2 used by the recipe preparation agency for explanation.

[0095] (Step S110) Terminal 1 sends a sender ID, a receiver ID, and dragID as drug identification information to management system 6. In this example, sender ID is information identifying a gene analysis organization using terminal 1, and receiver ID is information identifying a recipe preparation organization using terminal 2.

[0096] (Step S120) Next, the management system 6 creates a directory for the target content (here, genome information as an example) in the storage device 9.

[0097] (Step S130 ) Next, the management system 6 transmits the path of the created directory (also referred to as a directory path) to the terminal 1 .

[0098] (Step S140 ) The terminal 1 that has received the directory path saves the file containing the genome information into the directory indicated by the directory path of the storage device 9 .

[0099] (Step S150) Next, the terminal 1 transmits the electronic signature of the sender encrypted with the private key of the sender (here, as an example, the terminal 1 or the gene analysis organization) to the management system 6.

[0100] (Step S160) As an example, at the same time or in parallel, the terminal 1 sends the hash value of the file encrypted by the private key of the sender (here, as an example, the terminal 1 or the gene analysis agency) to the management system 6. Here, the hash value of the file is the hash value of the file of the object content (here, as an example, the genome information). In addition, the hash value of the file encrypted by the private key of the sender (here, as an example, the terminal 1 or the gene analysis agency) is used as information indicating that it has been encrypted by the private key of the sender, and "(S)" is appended to the end, which is also called the encrypted file hash value (S).

[0101] (Step S170) <First Writing Step> Next, the management system 6 records the first certification data including the encrypted file hash value (S) in one block of the blockchain 81. Figure 5 A specific example of step S31.

[0102] In the first write step to the blockchain ( Figure 6 An example of the first proof data written into the blockchain in step S180) is as follows.

[0103] dragID: drug identification information

[0104] encryptedContentHashValue_S: Information obtained by encrypting the hash value of the target content (in this case, genome information) using the sender's private key

[0105] senderID: The sender's identification information (the creator's identification information)

[0106] senderEsignature: The electronic signature of the sender (in this case, a genetic analysis agency)

[0107] RecieverID: The identification information of the recipient (here, for example, terminal 2 or a recipe making agency)

[0108] timestamp: the time of handover

[0109] Location: the place of handover

[0110] In addition, senderEsignature is set to the sender's electronic signature, but not limited to this, and the sender's electronic signature is set to the information obtained by encrypting the electronic signature with the sender's private key, but not limited to this, and it can also be the sender's electronic signature.

[0111] (Step S180) Next, the management system 6 sends the file path and the location of the record of the blockchain recorded in step S170 to the terminal 2 of the recipient.

[0112] (Step S190) For example, the receiving terminal 2 requests the encrypted file hash value (S). In response to the request, the management system 6 sends the encrypted file hash value (S) and the blockchain record to the terminal 2.

[0113] The processing of step S190 may also replace the above processing, whereby the management system 6 sends the encrypted file hash value (S) and the blockchain record to the terminal 2 in the absence of a request from the terminal 2.

[0114] (Step S200 ) The terminal 2 acquires a file including target content (here, genome information as an example) from the storage device 9 .

[0115] (Step S210) Then, terminal 2 decrypts the encrypted file hash value (S) using the public key, and compares the decrypted value with the hash value of the file obtained in step S200 to determine whether they are consistent. Here, the public key corresponds to the private key of the sender (here as an example, terminal 1 or a gene analysis agency) used for encryption in step S150. If decryption can be performed using the public key, it proves that the encrypted file hash value (S) was created by the owner of the private key (here as an example, terminal 1 or a gene analysis agency). Furthermore, if the decrypted value is consistent with the hash value of the file obtained in step S200, it proves that the file obtained in step S200 is the true object content (here as an example, genome information).

[0116] (Step S220) When the value decrypted by step S210 is consistent with the hash value of the file obtained in step S200, terminal 2 sends the electronic signature of the recipient encrypted by the recipient's private key (here as an example, the recipe preparation organization) to the management system 6.

[0117] (Step S230) As an example, at the same time or in parallel, the terminal 2 sends the hash value of the file encrypted by the private key of the recipient (here, as an example, the terminal 2 or the recipe making mechanism) to the management system 6. Here, the hash value of the file is the hash value of the file of the object content (here, as an example, the genome information). In addition, the hash value of the file encrypted by the private key of the recipient (here, as an example, the terminal 2 or the recipe making mechanism) is used as information indicating that it has been encrypted by the private key of the recipient, and "(R)" is added to the end, which is also called the encrypted file hash value (R).

[0118] (Step S240) <Second Writing Step> Next, the management system 6 records the second certification data including the encrypted file hash value (R) in a block of the blockchain 81. The block recorded here is, for example, a block different from the block in step S170.

[0119] In the second write step of the blockchain ( Figure 6 An example of the second proof data written to the blockchain in step S240) is as follows.

[0120] dragID: drug identification information

[0121] encryptedContentHashValue_R: Information obtained by encrypting the hash value of the target content (in this case, genome information) using the recipient's private key

[0122] RecieverEsignature: The electronic signature of the recipient (in this case, the recipe production agency)

[0123] timestamp: the time of electronic signature

[0124] In addition, recipientEsignature is set to the electronic signature of the recipient, but it is not limited to this, and it can also be information obtained by encrypting the electronic signature of the recipient with the private key of the recipient.

[0125] (Step S250 ) The management system 6 sends the dragID of the object, the file of the object content (here, genome information as an example), the encrypted file hash value (S), and the encrypted file hash value (R) to the authentication system 7 .

[0126] (Step S260) Upon receiving the dragID of the object, the file of the object content (here, genome information as an example), the encrypted file hash value (S), and the encrypted file hash value (R), the authentication system 7 verifies whether the object content is properly transferred in each exchange unit, and if the result of the verification is that it is properly transferred, the authentication system 7 performs the following processing. For example, the authentication system 7 retrieves the block of the blockchain 81 from the blockchain 81 using the dragID of the drug identification information as the object as a keyword, and if the result of the retrieval is that the hash values ​​contained in the two blocks obtained are consistent, the authentication system 7 verifies that the transfer of the object content is normally performed. At this time, specifically, for example, the authentication system 7 decrypts the encrypted file hash value (S) contained in one block using the public key corresponding to the private key of the terminal 1 as the sender to obtain the file hash value (S), decrypts the encrypted file hash value (R) using the public key corresponding to the private key of the terminal 2 as the receiver to obtain the file hash value (R), and implements the judgment of whether the file hash value (S) and the file hash value (R) are consistent.

[0127] Thus, it is possible to verify that the object content (here, genome information as an example) is properly handed over, and if it is appropriate, the situation is authenticated. In addition, as an example of information based on the first hash value, the first certification data includes information obtained by encrypting the first hash value with the first private key, but is not limited to this, and may also include the first hash value itself.

[0128] In summary, the information processing system 10 is an information processing system including the terminal 1 , the terminal 2 , and the management system 6 .

[0129] Terminal 1 outputs a first hash value based on data at least including the genome information of the target patient, and sends first proof data including the first hash value or information based on the first hash value (for example, information obtained by encrypting the first hash value with a first private key). Here, the data at least including the genome information of the target patient may include at least one of the type of disease, medical history, HLA type, and gender of the target patient. Management system 6 records the first proof data received from terminal 1 to the blockchain. Management system 6 may also send storage location data (for example, a file path) indicating the storage location of the above-mentioned genome information to terminal 2. Management system 6 reads out the first proof data recorded in the above-mentioned blockchain and sends the first proof data to terminal 2. Terminal 2 obtains the first hash value based on the first proof data received from management system 6, for example, reads out the above-mentioned genome information from the area of ​​the storage device indicated by the received storage location data, generates a second hash value based on the genome information, and determines whether the first hash value is consistent with the second hash value.

[0130] According to this structure, if the first hash value recorded in the blockchain matches the second hash value generated based on the genome information, it is ensured that the two are the same genome information, so the authenticity of the genome information of the target patient can be ensured.

[0131] In addition, when sending the first certification data, terminal 1 sends information obtained by encrypting the first hash value using the first private key. When terminal 2 obtains the first hash value included in the first certification data, it decrypts the first certification data using the first public key corresponding to the first private key to obtain the first hash value. In addition, the first public key can be held by terminal 2 or input to terminal 2 by a recipe making mechanism using terminal 2.

[0132] According to this structure, since the first private key is only held by the gene analysis organization using terminal 1, it can be ensured that the gene analysis organization participates in encryption and participates in the generation of genome information as a party, that is, the authenticity of the party generating genome information can be ensured.

[0133] In addition, the first certification data received from the terminal 1 recorded in the blockchain 81 contains drug identification information identifying the personalized drug for the target patient. When the first hash value is consistent with the second hash value, the terminal 2 sends the second certification data containing the drug identification information and the second hash value (specifically, for example, a file hash value or an encrypted file hash value (R)). In addition, in this case, since the second hash value is consistent with the first hash value, the first hash value may be sent instead of the second hash value. Next, the management system 6 records the second certification data received from the terminal 2 to the blockchain.

[0134] According to this structure, in addition to the first proof data, the second proof data is also recorded in the blockchain. Then, by verifying whether the first hash value contained in the first proof data recorded in the blockchain is consistent with the second hash value contained in the second proof data, it is possible to verify whether the genome information handover transaction is carried out normally. As an example, this verification can be performed by the authentication system 7.

[0135] Specifically, for example, as described above, the authentication system 7 can use the drug identification information of the object as a keyword to search the block of the blockchain, and when the result of the search is that the hash values ​​contained in the two blocks obtained are consistent, it is determined that the handover of the genome information has been carried out normally. According to this structure, it is possible to authenticate that the handover of the genome information has been carried out normally.

[0136] In addition, Figure 6 In the example, the target content is the genome information of the target patient, the sender is the terminal 1 used by the gene analysis agency, and the receiver is the terminal 2 used by the formulation production agency, but the present invention is not limited to this. Alternatively, the target content is the vaccine formulation for the target patient, the sender is the terminal 2 used by the formulation production agency, and the receiver is the terminal 3 used by the drug manufacturing agency.

[0137] In this case, Figure 6 A series of processing can be as follows.

[0138] (Step S110) Terminal 2 sends a sender ID, a receiver ID, and dragID as drug identification information to management system 6. In this example, sender ID is information identifying a recipe making organization using terminal 2, and receiver ID is information identifying a drug manufacturing organization using terminal 3.

[0139] (Step S120 ) Next, the management system 6 creates a directory for the target content (recipe data as an example in this example) in the storage device 9 .

[0140] (Step S130 ) Next, the management system 6 transmits the path of the created directory (also referred to as a directory path) to the terminal 3 .

[0141] (Step S140 ) The terminal 3 , which has received the directory path, saves the file including the recipe data in the directory indicated by the directory path of the storage device 9 .

[0142] (Step S150) Next, the terminal 2 transmits the electronic signature of the sender encrypted with the private key of the sender (here, as an example, the terminal 2 or the recipe preparation organization) to the management system 6.

[0143] (Step S160) As an example, at the same time or in parallel, the terminal 2 sends the hash value of the file encrypted by the private key of the sender (here, as an example, the terminal 2 or the recipe making mechanism) to the management system 6. Here, the hash value of the file is the hash value of the file of the object content (here, as an example, the recipe data). In addition, the hash value of the file encrypted by the private key of the sender (here, as an example, the terminal 2 or the recipe making mechanism) is used as information indicating that it is encrypted by the private key of the sender, and "(S)" is added to the end, which is also called the encrypted file hash value (S).

[0144] (Step S170) <First Writing Step> Next, the management system 6 records the first certification data including the encrypted file hash value (S) in one block of the blockchain 81. Figure 5 A specific example of step S41.

[0145] In the first write step to the blockchain ( Figure 6 An example of the first proof data written into the blockchain in step S180) is as follows.

[0146] dragID: drug identification information

[0147] encryptedContentHashValue_S: Information obtained by encrypting the hash value of the target content (here, a file containing recipe data as an example) using the private key of the sender

[0148] senderID: The sender's identification information (the creator's identification information)

[0149] senderEsignature: The electronic signature of the sender (in this case, the recipe production agency)

[0150] RecieverID: identification information of the recipient (here, for example, terminal 3 or a drug manufacturing organization)

[0151] timestamp: the time of handover

[0152] Location: the place of handover

[0153] In addition, senderEsignature is set to the sender's electronic signature, but not limited to this, and the sender's electronic signature is set to the information obtained by encrypting the electronic signature with the sender's private key, but not limited to this, and it can also be the sender's electronic signature.

[0154] (Step S180) Next, the management system 6 sends the file path and the location of the record of the blockchain recorded in step S170 to the terminal 3 of the recipient.

[0155] (Step S190) For example, the receiving terminal 3 requests the encrypted file hash value (S). In response to the request, the management system 6 sends the encrypted file hash value (S) and the blockchain record to the terminal 3.

[0156] The processing of step S190 may also replace the above processing, whereby the management system 6 sends the encrypted file hash value (S) and the blockchain record to the terminal 3 in the absence of a request from the terminal 3 .

[0157] (Step S200 ) The terminal 2 acquires a file including target content (recipe data as an example in this example) from the storage device 9 .

[0158] (Step S210) Next, the terminal 2 decrypts the encrypted file hash value (S) using the public key, and compares the decrypted value with the hash value of the file obtained in step S200 to determine whether they are consistent. Here, the public key corresponds to the private key of the sender (here, as an example, the terminal 2 or the recipe making organization) used for encryption in step S150. If the public key can be decrypted, it proves that the encrypted file hash value (S) was created by the owner of the private key (here, as an example, the terminal 2 or the recipe making organization). And, if the decrypted value is consistent with the hash value of the file obtained in step S200, it proves that the file obtained in step S200 is the real object content (here, as an example, the recipe data).

[0159] (Step S220) When the value decrypted by step S210 is consistent with the hash value of the file obtained in step S200, terminal 3 sends the electronic signature of the recipient encrypted by the recipient's private key (here as an example, a drug manufacturing organization) to the management system 6.

[0160] (Step S230) As an example, at the same time or in parallel, the terminal 3 sends the hash value of the file encrypted by the private key of the recipient (here, as an example, the terminal 3 or the drug manufacturing organization) to the management system 6. Here, the hash value of the file is the hash value of the file of the object content (here, as an example, the recipe data). In addition, the hash value of the file encrypted by the private key of the recipient (here, as an example, the terminal 3 or the drug manufacturing organization) is used as information indicating that it has been encrypted by the private key of the recipient, and "(R)" is added to the end, which is also called the encrypted file hash value (R).

[0161] (Step S240) <Second Writing Step> Next, the management system 6 records the second certification data including the encrypted file hash value (R) in one block of the blockchain 81. Here, the recorded block is, for example, a block different from the block in step S170.

[0162] In the second write step of the blockchain ( Figure 6 An example of the second proof data written into the blockchain in step S240) is as follows.

[0163] dragID: drug identification information

[0164] encryptedContentHashValue_R: Information obtained by encrypting the hash value of the target content (recipe data in this example) using the recipient's private key

[0165] RecieverEsignature: The electronic signature of the recipient (in this case, a pharmaceutical manufacturer)

[0166] timestamp: the time of electronic signature

[0167] In addition, recipientEsignature is set to the electronic signature of the recipient, but it is not limited to this, and it can also be information obtained by encrypting the electronic signature of the recipient with the private key of the recipient.

[0168] (Step S250 ) The management system 6 sends the dragID of the object, the file of the object content (recipe data as an example in this case), the encrypted file hash value (S), and the encrypted file hash value (R) to the authentication system 7 .

[0169] (Step S260) Upon receiving the dragID of the object, the file of the object content (here, as an example, the recipe data), the encrypted file hash value (S), and the encrypted file hash value (R), the authentication system 7 verifies whether the object content is properly transferred in each exchange unit, and if the result of the verification is that it is properly transferred, the authentication system 7 performs the following processing. For example, the authentication system 7 retrieves the block of the blockchain 81 from the blockchain 81 using the dragID of the drug identification information as the object as a keyword, and if the result of the retrieval is that the hash values ​​contained in the two blocks obtained are consistent, the authentication system 7 verifies that the transfer of the object content is normally performed. At this time, specifically, for example, the authentication system 7 decrypts the encrypted file hash value (S) contained in one block using the public key corresponding to the private key of the terminal 2 as the sender to obtain the file hash value (S), decrypts the encrypted file hash value (R) using the public key corresponding to the private key of the terminal 3 as the receiver to obtain the file hash value (R), and implements the judgment of whether the file hash value (S) and the file hash value (R) are consistent.

[0170] Thus, it is possible to verify that the object content (here, as an example, recipe data) has been properly handed over, and if appropriate, the situation is authenticated. In addition, as an example of information based on the third hash value, the third proof data includes information obtained by encrypting the third hash value with the third private key, but is not limited to this, and may also include the third hash value itself.

[0171] In this way, the terminal 2 outputs a third hash value based on data that at least includes a formula of a drug for the target patient (e.g., a vaccine formula), and sends third proof data including the third hash value or information based on the third hash value (e.g., information obtained by encrypting the third hash value with a third private key). The management system 6 records the third proof data received from the terminal 2 to the blockchain. The management system 6 may also send storage location data (e.g., a file path) indicating the storage location of the above-mentioned formula to the terminal 2. The management system 6 sends the third proof data recorded in the blockchain to the terminal 3. The terminal 3 obtains the third hash value based on the third proof data received from the management system 6, reads the above-mentioned formula from the area of ​​the storage device indicated by the received storage location data, generates a fourth hash value based on the formula, and determines whether the third hash value is consistent with the fourth hash value.

[0172] According to this structure, if the first hash value recorded in the blockchain is consistent with the fourth hash value generated based on the recipe, it is ensured that the two are the same recipe, so the authenticity of the recipe can be ensured.

[0173] In addition, when sending the third certification data, terminal 2 may also send information obtained by encrypting the third hash value using the second private key. In this case, when obtaining the third hash value included in the third certification data, terminal 3 may decrypt the third certification data using the second public key corresponding to the second private key, thereby obtaining the second hash value.

[0174] According to this structure, since the second private key is held only by the recipe preparation organization using terminal 2, it is possible to ensure that the recipe preparation organization participates in encryption and participates in recipe generation as a party, that is, the authenticity of the recipe preparation party can be ensured.

[0175] In addition, the third certification data received from the terminal 2 and recorded in the blockchain 81 may include drug identification information identifying the personalized drug for the target patient. In this case, the terminal 3 may send fourth certification data including the drug identification information and the third hash value or the fourth hash value when the third hash value is consistent with the fourth hash value. In this case, the management system 6 may record the fourth certification data received from the terminal 3 in the blockchain.

[0176] According to this structure, in addition to the third proof data, the fourth proof data is also recorded in the blockchain. Then, by verifying whether the third hash value included in the third proof data recorded in the blockchain is consistent with the fourth hash value included in the fourth proof data, it is possible to verify whether the recipe handover transaction is carried out normally. This verification is performed by the authentication system 7 as an example.

[0177] Specifically, for example, the authentication system 7 can use the drug identification information of the object as a keyword to search the block of the blockchain, and when the result of the search is that the hash values ​​contained in the two blocks obtained are consistent, it is determined that the handover of the prescription has been carried out normally. According to this structure, it is possible to authenticate that the handover of the prescription has been carried out normally.

[0178] In addition, the terminal 4 may send fifth certification data for proving that the sample of the target patient has been delivered from the medical institution to the logistics company. In this case, the management system 6 may record the fifth certification data received from the terminal 4 to the blockchain 81. Furthermore, in this case, the terminal 5 may send sixth certification data for proving that the logistics company has received the sample of the target patient from the medical institution. Furthermore, in this case, the management system 6 may record the sixth certification data received from the terminal 5 to the blockchain 81.

[0179] According to this configuration, it is possible to verify later that the sample from the target patient was normally delivered.

[0180] Here, the fifth certification data may include information obtained by encrypting the hash value of the text data for personalized medicine using the third private key used by the medical institution. In addition, the sixth certification data may include information obtained by encrypting the hash value of the text data for personalized medicine using the fourth private key used by the logistics company.

[0181] As described above, the information processing system 10 of the present embodiment is an information processing system having a first terminal, a second terminal and a management system, wherein the first terminal outputs a first hash value based on data at least including the object content, and sends first proof data containing the first hash value or information based on the first hash value (for example, information obtained by encrypting the first hash value with a first private key). The management system records the first proof data received from the first terminal to the blockchain. The management system sends the first proof data recorded in the blockchain to the above-mentioned second terminal. The second terminal obtains the first hash value based on the first proof data received from the management system. In the case where the information based on the first hash value contained in the first proof data is information obtained by encrypting the first hash value with a first private key, the process of obtaining includes decryption by a first public key corresponding to the first private key. Then, the second terminal obtains the above-mentioned object content, for example, based on the storage area of ​​the storage device indicated by the storage location data (for example, a file path) received from the management system, generates a second hash value based on the object content, and determines whether the first hash value is consistent with the second hash value.

[0182] Here, the first terminal and the second terminal can be terminal 1 and terminal 2, respectively, or terminal 2 and terminal 3, or terminal 2 and terminal 3, or terminal 4 and terminal 5, or terminal 5 and terminal 1, or terminal 3 and terminal 4, or terminal 5 and terminal 4.

[0183] Therefore, if the first hash value recorded in the blockchain is consistent with the second hash value generated based on the object content, it is ensured that the two are the same object content, so the authenticity of the object content can be ensured.

[0184] In addition, the storage device 9 is described as being separate from the management system 6, but is not limited to this, and may also be built into the management system 6. In addition, in one of the above-mentioned methods, as an example, the object content (such as genome information or recipe data) is exchanged via the storage device 9. In the case where the object content has a large amount of data, such as genome information, the exchange can be smoothly performed through the storage device 9. However, it is not limited to this, and the exchange may also be performed without going through the storage device 9. For example, the second terminal may directly receive the object content from the first terminal or the management system, and the user using the second terminal may physically receive the memory storing the object content through distribution, etc. and store it in the second terminal. As long as the second terminal can obtain the object content, its acquisition path is not restricted.

[0185] In addition, at least a part of the management system 6 or the terminals 1 to 5 described in the above-mentioned embodiment may be constituted by hardware or software. In the case of being constituted by software, a program that realizes at least a part of the functions of the management system 6 or the terminals 1 to 5 may be stored in a computer-readable recording medium so that the computer reads and executes it. The recording medium is not limited to a removable recording medium such as a magnetic disk or an optical disk, but may also be a fixed recording medium such as a hard disk device or a memory.

[0186] In addition, the program that realizes at least a part of the functions of the management system 6 or the terminals 1 to 5 may be distributed via a communication network such as the Internet (including wireless communication). Furthermore, the program may be encrypted, modulated, or distributed in a compressed state via a wired network such as the Internet, a wireless network, or stored in a recording medium.

[0187] Furthermore, the management system 6 may be made to function by one or more information devices. When a plurality of information devices are used, one of them may be a computer, and the computer may execute a predetermined program to realize the function of at least one means of the management system 6.

[0188] In addition, in the invention of the method, all processes (steps) can be realized by automatic control by a computer. In addition, each process can be implemented by a computer while the control between processes can be implemented manually. In addition, at least a part of all processes can be implemented manually.

[0189] As mentioned above, the present invention is not limited to the above-mentioned embodiments themselves. In the implementation stage, the constituent elements can be deformed and embodied within the scope of the main purpose. In addition, various inventions can be formed by appropriate combinations of multiple constituent elements disclosed in the above-mentioned embodiments. For example, several constituent elements can also be deleted from all the constituent elements shown in the embodiments. Furthermore, constituent elements can also be appropriately combined across different embodiments.

[0190] Description of symbols

[0191] 1 Terminal

[0192] 10 Information Processing System

[0193] 11 Input Interface

[0194] 12 Communication Module

[0195] 13 Storage Devices

[0196] 14 Memory

[0197] 15 Output interface

[0198] 16 Processors

[0199] 2 Terminal

[0200] 3 Terminal

[0201] 4 Terminal

[0202] 5 Terminal

[0203] 6 Management System

[0204] 61 Input interface

[0205] 62 Communication Module

[0206] 63 Storage Device

[0207] 64 Memory

[0208] 65 Output interface

[0209] 66 processors

[0210] 7 Authentication System

[0211] 71 Input interface

[0212] 72 Communication Module

[0213] 73 Storage Device

[0214] 74 Memory

[0215] 75 Output interface

[0216] 76 processors

[0217] 8 Distributed Network

[0218] 81 Blockchain

[0219] 9 Storage Devices

Claims

1. An information processing system, comprising a first terminal, a second terminal and a management system, wherein: The first terminal outputs a first hash value based on data at least including the target content, and sends first certification data, wherein the first certification data includes either the first hash value or information based on the first hash value. The management system records the first certification data received from the first terminal to the blockchain, The management system sends the first certification data recorded in the blockchain to the second terminal, The second terminal obtains a first hash value according to the first certification data received from the management system, obtains the object content and generates a second hash value according to the object content, and determines whether the first hash value is consistent with the second hash value.

2. The information processing system according to claim 1, wherein: The first terminal is used by a gene analysis institution that generates genome information of a target patient based on a sample of the target patient. The second terminal is used by a formulation preparation institution that prepares the vaccine formulation. The object content is the genome information of the object patient.

3. The information processing system according to claim 2, wherein: The genome information of the subject patient includes gene data of cancer cells of the subject patient and gene data of normal cells of the subject patient.

4. The information processing system according to claim 1, wherein: The first terminal is used by a formulation preparation institution that prepares the vaccine formulation. The second terminal is used by a pharmaceutical manufacturing organization that manufactures personalized medicines based on vaccine formulations. The subject content is a vaccine formulation for a subject patient.

5. The information processing system according to any one of claims 1 to 4, wherein: The information based on the first Hash value is information obtained by encrypting the first Hash value with a first private key, When sending the first certification data, the first terminal sends information obtained by encrypting the first hash value with the first private key. When obtaining the first hash value included in the first certification data, the second terminal decrypts the first certification data using the first public key corresponding to the first private key, thereby obtaining the first hash value.

6. The information processing system according to any one of claims 1 to 5, wherein: The first certification data recorded in the blockchain and received from the first terminal contains drug identification information identifying a personalized drug for a target patient, When the first hash value is consistent with the second hash value, the second terminal sends second certification data including drug identification information and the first hash value or the second hash value. The management system records the second certification data received from the second terminal into the blockchain.

7. The information processing system according to claim 6, wherein: The information processing system also has an authentication system. The authentication system uses the drug identification information of the object as a keyword to search the blocks of the blockchain. When the search result shows that the hash values ​​contained in the two blocks obtained are consistent, it is determined that the handover of the object content has been carried out normally.

8. The information processing system according to claim 2 or 3, wherein: The information processing system also has a third terminal, which is used by a pharmaceutical manufacturing organization that manufactures personalized medicines based on vaccine formulations. The second terminal outputs a hash value based on data at least including a prescription of a drug for a target patient, and transmits third certification data, wherein the third certification data includes either the hash value or information based on the hash value. The management system records the third certification data received from the second terminal into the blockchain, The management system sends the third certification data recorded in the blockchain to the third terminal, The third terminal obtains a fourth hash value included in the third certification data received from the management system, obtains the recipe and generates a fourth hash value according to the recipe, and determines whether the third hash value is consistent with the fourth hash value.

9. The information processing system according to claim 8, wherein: When sending the third certification data, the second terminal sends information obtained by encrypting the third hash value with the second private key, When obtaining the third hash value included in the third certification data, the third terminal decrypts the third certification data using the second public key corresponding to the second private key, thereby obtaining the second hash value.

10. The information processing system according to claim 8 or 9, wherein: The third certification data recorded in the blockchain and received from the second terminal contains drug identification information identifying the personalized drug for the target patient, The third terminal sends fourth certification data including drug identification information and the third hash value or the fourth hash value when the third hash value is consistent with the fourth hash value, The management system records the fourth certification data received from the third terminal into the blockchain.

11. The information processing system according to any one of claims 1 to 10, wherein: The information processing system has a fourth terminal used by a medical institution and a fifth device used by a logistics company, The fourth terminal sends fifth certification data for proving that the sample of the target patient has been delivered from the medical institution to the logistics company, The management system records the fifth certification data received from the fourth terminal into the blockchain, The fifth terminal sends sixth certification data for proving that the logistics company has received the sample of the target patient from the medical institution, The management system records the sixth certification data received from the fifth terminal into the blockchain.

12. The information processing system according to claim 11, wherein: The fifth certification data includes information obtained by encrypting the hash value of the text data for personalized medicine using the third private key used by the medical institution. The sixth certification data includes information obtained by encrypting the hash value of the text data for personalized medicine using the fourth private key used by the logistics company.

13. An information processing method comprising: The first terminal outputs a first hash value according to data at least including the object content, and sends first certification data, wherein the first certification data includes either the first hash value or information based on the first hash value; The management system records the first certification data received from the first terminal into the blockchain; The management system sends the first certification data recorded in the blockchain to the second terminal; as well as The second terminal obtains a first hash value according to the first certification data received from the management system, obtains the object content and generates a second hash value according to the object content, and determines whether the first hash value is consistent with the second hash value.

14. A program for causing a computer to execute the following steps: A step of obtaining a first hash value from first certification data recorded in the blockchain, wherein the first certification data includes a first hash value generated based on data including at least the target content or information based on the first hash value; A step of generating a second hash value according to the object content; as well as The step of determining whether the first Hash value is consistent with the second Hash value.

Images